Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Common Equity: 2014-2025

Historic Common Equity for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $503.0 million.

  • Viridian Therapeutics, Inc.\DE's Common Equity fell 28.91% to $503.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $503.0 million, marking a year-over-year decrease of 28.91%. This contributed to the annual value of $671.6 million for FY2024, which is 51.95% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Common Equity stood at $503.0 million for Q3 2025, which was down 2.37% from $515.2 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Common Equity registered a high of $707.5 million during Q3 2024, and its lowest value of $98.9 million during Q2 2021.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's Common Equity had a median value of $515.2 million in 2025 and averaged $500.5 million.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 872.30% in 2021, then slumped by 30.67% in 2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Common Equity (Quarterly) stood at $187.7 million in 2021, then skyrocketed by 110.46% to $395.1 million in 2022, then grew by 11.89% to $442.0 million in 2023, then spiked by 51.95% to $671.6 million in 2024, then declined by 28.91% to $503.0 million in 2025.
  • Its Common Equity was $503.0 million in Q3 2025, compared to $515.2 million in Q2 2025 and $604.5 million in Q1 2025.